Home Cart Sign in  
Chemical Structure| 1001600-56-1 Chemical Structure| 1001600-56-1

Structure of BV6
CAS No.: 1001600-56-1

Chemical Structure| 1001600-56-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BV6 acts as an antagonist targeting cIAP1 and XIAP, which are members of the inhibitors of apoptosis (IAP) family.

Synonyms: BV-6 free

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BV6

CAS No. :1001600-56-1
Formula : C70H96N10O8
M.W : 1205.57
SMILES Code : O=C(NCCCCCCNC([C@@H](NC([C@H](CCC1)N1C([C@H](C2CCCCC2)NC([C@H](C)NC)=O)=O)=O)C(C3=CC=CC=C3)C4=CC=CC=C4)=O)[C@@H](NC([C@H](CCC5)N5C([C@H](C6CCCCC6)NC([C@H](C)NC)=O)=O)=O)C(C7=CC=CC=C7)C8=CC=CC=C8
Synonyms :
BV-6 free
MDL No. :MFCD28168021

Safety of BV6

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Acute lymphoblastic leukemia cells 300 nM 24 hours Induces necroptotic cell death Cell Death Differ. 2017 Jan;24(1):83-97.
HT29 cells 2 µM 1, 2, 4 hours Induction of necroptosis in HT29 cells, stimulating RIP1 ubiquitination within the necrosome Cell Death Differ. 2017 Jan;24(1):26-37.
GBM9 cells 0.6 µM 10 days BV6 stimulates morphological changes in GBM9 cells and increases GFAP expression, indicating that BV6 induces astrocytic differentiation of GBM9 cells. Cell Death Differ. 2014 May;21(5):735-47.
A172 glioblastoma cells 2 µM 120 hours BV6 enhances TMZ-induced apoptosis, and upregulation of IFNβ is a critical event in BV6/TMZ-induced apoptosis. Cell Death Dis. 2015 Sep 17;6(9):e1888.
T98G glioblastoma cells 4 µM 120 hours BV6 enhances TMZ-induced apoptosis, and upregulation of IFNβ is a critical event in BV6/TMZ-induced apoptosis. Cell Death Dis. 2015 Sep 17;6(9):e1888.
L929 cells 1 µM 2 hours BV6 treatment greatly sensitized L929 cells to TNF-induced necrosis, but not to necrotic death induced by anti-Fas, poly(I:C), or oxidative stress. Cell Death Differ. 2011 Apr;18(4):656-65.
Mouse embryonic fibroblasts 5 µM 24 hours Protects cells from BV6/Dexa-induced cell death Cell Death Differ. 2017 Jan;24(1):83-97.
HCC193 1 µM 24 hours BV6 significantly enhanced the radiosensitivity of HCC193 cells, DER=1.38 (p<0.05). J Thorac Oncol. 2011 Nov;6(11):1801-9.
FADD-deficient Jurkat T cells 1 µM 24 hours BV6 treatment sensitized FADD-deficient Jurkat T cells to TNF-induced necrosis. Cell Death Differ. 2011 Apr;18(4):656-65.
T98G cells 2.5 µM 24 hours BV6 at non-toxic concentrations triggers cell elongation, migration, and invasion, and causes profound depletion of cIAP1 protein. Cell Death Dis. 2013 Mar 28;4(3):e564.
U87MG cells 2.5 µM 24 hours BV6 at non-toxic concentrations triggers cell migration and invasion, and causes degradation of cIAP1 and XIAP proteins. Cell Death Dis. 2013 Mar 28;4(3):e564.
LN229 cells 2.5 µM 24 hours BV6 at non-toxic concentrations triggers cell migration and invasion, and causes degradation of cIAP1 and XIAP proteins. Cell Death Dis. 2013 Mar 28;4(3):e564.
GBM1 cells 1 µM 24 hours BV6 at non-toxic concentrations triggers cell elongation, migration, and invasion, and causes profound depletion of cIAP1 protein. Cell Death Dis. 2013 Mar 28;4(3):e564.
GBM2 cells 0.8 µM 24 hours BV6 at non-toxic concentrations triggers cell elongation, migration, and invasion, and causes profound depletion of cIAP1 protein. Cell Death Dis. 2013 Mar 28;4(3):e564.
AsPc-1 5 µM 48 hours To investigate whether BV6 combined with 2′3′-cGAMP can induce necroptosis in apoptosis-deficient pancreatic cancer cells, the results showed that BV6 combined with 2′3′-cGAMP significantly increased cell death, and this death could be reduced by Nec-1s inhibition of RIPK1, indicating RIPK1-dependent necroptotic cell death. Cell Death Dis. 2021 Aug 30;12(9):816.
BxPc-3 5 µM 48 hours To investigate whether BV6 combined with 2′3′-cGAMP can induce necroptosis in apoptosis-deficient pancreatic cancer cells, the results showed that BV6 combined with 2′3′-cGAMP significantly increased cell death, and this death could be reduced by Nec-1s inhibition of RIPK1, indicating RIPK1-dependent necroptotic cell death. Cell Death Dis. 2021 Aug 30;12(9):816.
Capan-1 5 µM 48 hours To investigate whether BV6 combined with 2′3′-cGAMP can induce necroptosis in apoptosis-deficient pancreatic cancer cells, the results showed that BV6 combined with 2′3′-cGAMP significantly increased cell death, and this death could be reduced by Nec-1s inhibition of RIPK1, indicating RIPK1-dependent necroptotic cell death. Cell Death Dis. 2021 Aug 30;12(9):816.
DanG 5 µM 48 hours To investigate whether BV6 combined with 2′3′-cGAMP can induce necroptosis in apoptosis-deficient pancreatic cancer cells, the results showed that BV6 combined with 2′3′-cGAMP significantly increased cell death, and this death could be reduced by Nec-1s inhibition of RIPK1, indicating RIPK1-dependent necroptotic cell death. Cell Death Dis. 2021 Aug 30;12(9):816.
H460 5 µM 48 hours BV6 significantly enhanced the radiosensitivity of H460 cells, DER=1.42 (p<0.05). J Thorac Oncol. 2011 Nov;6(11):1801-9.
UoCB6 66.1 nM 48 hours BV6 induced cell death, primarily through TNF-α-dependent apoptosis Cell Death Dis. 2016 Jan 14;7(1):e2052.
REH 251.1 nM 48 hours BV6 induced cell death, primarily through TNF-α-dependent apoptosis Cell Death Dis. 2016 Jan 14;7(1):e2052.
GBM10 cells 1 µM 7 days BV6 stimulates morphological changes in GBM10 cells and increases GFAP expression, indicating that BV6 induces astrocytic differentiation of GBM10 cells. Cell Death Differ. 2014 May;21(5):735-47.
Non-malignant neural stem cells (NSCs) 1 µM 7 days BV6 does not alter cell morphology, differentiation, or expression of stemness markers in NSCs. Cell Death Differ. 2014 May;21(5):735-47.
A172 glioblastoma cells 5 µM 72 hours To investigate the mechanism of BV6-induced apoptosis, it was found that BV6 upregulates DR5 expression in an NF-κB-dependent manner, thereby promoting apoptosis. Cell Death Dis. 2013 Nov 28;4(11):e936.
MDA-MB-231 breast carcinoma cells 50 nM 72 hours To investigate the mechanism of BV6-induced apoptosis, it was found that BV6 induces apoptosis through the TNFα/TNFR1 autocrine/paracrine signaling pathway. Cell Death Dis. 2013 Nov 28;4(11):e936.
MDA-MB-231 cells 50 nM 72 hours To evaluate BV6-induced cell death, results showed that IRF1 knockdown significantly reduced BV6-induced cell death. Cell Death Dis. 2014 Dec 11;5(12):e1562.
T24 cells 100 nM 72 hours To evaluate BV6-induced cell death, results showed that IRF1 knockdown significantly reduced BV6-induced cell death. Cell Death Dis. 2014 Dec 11;5(12):e1562.
SK-N-AS cells 50 nM 72 hours To evaluate BV6-induced cell death, results showed that IRF1 knockdown significantly reduced BV6-induced cell death. Cell Death Dis. 2014 Dec 11;5(12):e1562.
Kym1 cells 100 nM 72 hours To evaluate BV6-induced cell death, results showed that IRF1 knockdown significantly reduced BV6-induced cell death. Cell Death Dis. 2014 Dec 11;5(12):e1562.
H1299 cells 1 µM various time periods To evaluate the effect of BV6 on cIAP1 and cIAP2 protein levels, results showed that cIAP2 degradation was protected in H1299 cells Cell Death Differ. 2015 Sep;22(9):1463-76.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Athymic Nude mice Orthotopic and subcutaneous GBM models Injection 0.6 mM Single injection, observed until clinical symptoms appeared BV6 treatment reduces clonogenicity and tumorigenicity of GBM CSLCs in vivo and significantly increases the survival of mice. Cell Death Differ. 2014 May;21(5):735-47.
Nude mice Xenograft tumor model Intraperitoneal injection 10 mg/kg Every 4 days, total four treatments To evaluate the tumor suppressive effect of BV6, results showed that USP11 downregulation enhanced the antitumor activity of BV6 and TRAIL Cell Death Differ. 2015 Sep;22(9):1463-76.
NOD/SCID mice HuALL model Intraperitoneal injections 10 mg/kg Twice per week for 2 weeks BV6 significantly reduced leukemia load and prolonged leukemia-free survival, and this effect was dependent on TNF-α Cell Death Dis. 2016 Jan 14;7(1):e2052.
Chicken embryos Chicken chorioallantoic membrane model Implantation on the chicken chorioallantoic membrane 2.5 µM Single administration, lasting 4 days Pre-treatment with BV6 significantly increased the infiltrative growth of GBM cells, indicating that BV6 enhances the invasiveness of GBM cells in vivo. Cell Death Dis. 2013 Mar 28;4(3):e564.
WT and Ccr2−/− mice Acute sclerosing cholangitis model Intrabiliary injection single intrabiliary injection Single injection, continued for 5 days Inhibition of monocyte/macrophage recruitment by genetic or pharmacological depletion of CCR2 reduces biliary injury and fibrosis J Hepatol. 2018 Sep;69(3):676-686

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.83mL

0.17mL

0.08mL

4.15mL

0.83mL

0.41mL

8.29mL

1.66mL

0.83mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories